» Articles » PMID: 38396852

Epithelial-Mesenchymal Transition in Acute Leukemias

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Feb 24
PMID 38396852
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-mesenchymal transition (EMT) is a metabolic process that confers phenotypic flexibility to cells and the ability to adapt to new functions. This transition is critical during embryogenesis and is required for the differentiation of many tissues and organs. EMT can also be induced in advanced-stage cancers, leading to further malignant behavior and chemotherapy resistance, resulting in an unfavorable prognosis for patients. Although EMT was long considered and studied only in solid tumors, it has been shown to be involved in the pathogenesis of hematological malignancies, including acute leukemias. Indeed, there is increasing evidence that EMT promotes the progression of acute leukemias, leading to the emergence of a more aggressive phenotype of the disease, and also causes chemotherapy resistance. The current literature suggests that the levels and activities of EMT inducers and markers can be used to predict prognosis, and that targeting EMT in addition to conventional therapies may increase treatment success in acute leukemias.

Citing Articles

Comprehensive Analysis Reveals the Potential Diagnostic Value of Biomarkers Associated With Aging and Circadian Rhythm in Knee Osteoarthritis.

Li H, Yang Y, Li B, Yang J, Liu P, Gao Y Orthop Surg. 2025; 17(3):922-938.

PMID: 39846237 PMC: 11872380. DOI: 10.1111/os.14370.


The theragnostic advances of exosomes in managing leukaemia.

Ghosh S, Dey A, Chakrabarti A, Bhuniya T, Indu N, Hait A J Cell Mol Med. 2024; 28(23):e70052.

PMID: 39659020 PMC: 11632122. DOI: 10.1111/jcmm.70052.


Investigating the biology of microRNA links to ALDH1A1 reveals candidates for preclinical testing in acute myeloid leukemia.

Vlahopoulos S, Varisli L, Zoumpourlis P, Spandidos D, Zoumpourlis V Int J Oncol. 2024; 65(6).

PMID: 39513593 PMC: 11575927. DOI: 10.3892/ijo.2024.5703.


Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin.

Vlahopoulos S Int J Mol Sci. 2024; 25(16).

PMID: 39201306 PMC: 11354898. DOI: 10.3390/ijms25168621.


When DNA Mutations Interplay with Cellular Proliferation: A Narrative History of Theories of Carcinogenesis.

El Nachef L, Bouchet A, Bourguignon M, Foray N Cancers (Basel). 2024; 16(11).

PMID: 38893223 PMC: 11171183. DOI: 10.3390/cancers16112104.

References
1.
Zhang T, Zhou J, Ma J, Deng Z, Qian Z, Yao D . CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics. Clin Chem Lab Med. 2016; 55(1):123-131. DOI: 10.1515/cclm-2016-0205. View

2.
Arai F, Hosokawa K, Toyama H, Matsumoto Y, Suda T . Role of N-cadherin in the regulation of hematopoietic stem cells in the bone marrow niche. Ann N Y Acad Sci. 2012; 1266:72-7. DOI: 10.1111/j.1749-6632.2012.06576.x. View

3.
Kiyoi H, Kawashima N, Ishikawa Y . FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2019; 111(2):312-322. PMC: 7004512. DOI: 10.1111/cas.14274. View

4.
Graham T, Zhau H, Odero-Marah V, Osunkoya A, Kimbro K, Tighiouart M . Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008; 68(7):2479-88. DOI: 10.1158/0008-5472.CAN-07-2559. View

5.
Luo Y, Yu T, Zhang Q, Fu Q, Hu Y, Xiang M . Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis. Eur J Clin Invest. 2018; 48(4). PMC: 5887888. DOI: 10.1111/eci.12903. View